Clinical application of endothelial progenitor cell: Are we ready?

Acta Cardiologica Sinica

Volumn 29, Issue 6, 2013, Pages 479-487

  Wang, Chao Hung ^a,b   Huang, Po Hsun ^c,d   Chen, Jaw Wen ^c,d   Lin, Shing Jong ^c,d   Lee, Ming Feng ^a,b   Yang, Ning I ^a,b   Cherng, Wen Jin ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cardiovascular disease; Cell therapy; Endothelial progenitor cell; Smooth muscle progenitor cell

Indexed keywords

BIOLOGICAL FUNCTIONS; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CLINICAL TRIAL (TOPIC); COLONY FORMING CELL; EMBRYONIC STEM CELL; ENDOTHELIAL PROGENITOR CELL; EX VIVO STUDY; HUMAN; NONHUMAN; PLURIPOTENT STEM CELL; REVIEW; SMOOTH MUSCLE FIBER; STEM CELL; STEM CELL TRANSPLANTATION; VASCULITIS;

EID: 84891359152     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-7.
2. Kwon SM, Suzuki T, Kawamoto A, et al. Pivotal role of lnk adaptor protein in endothelial progenitor cell biology for vascular regeneration. Circ Res 2009;104:969-77.
3. Melero-Martin JM, Khan ZA, Picard A, et al. In vivo vasculogenic potential of human blood-derived endothelial progenitor cells. Blood 2007;109:4761-8.
4. Duan H, Cheng L, Sun X, et al. LFA-1 and VLA-4 involved in human high proliferative potential-endothelial progenitor cells homing to ischemic tissue. Thromb Haemost 2006;96:807-15.
5. Hristov M, Zernecke A, Liehn EA, Weber C. Regulation of endothelial progenitor cell homing after arterial injury. Thromb Haemost 2007;98:274-7.
6. Wang CH, Cherng WJ, Yang NI, et al. Late-outgrowth endothelial cells attenuate intimal hyperplasia contributed by mesenchymal stem cells after vascular injury. Arterioscler Thromb Vasc Biol 2008;28:54-60.
7. Das H, Abdulhameed N, Joseph M, et al. Ex vivo nanofiber expansion and genetic modification of human cord blood-derived progenitor/stem cells enhances vasculogenesis. Cell Transplant 2009;18:305-18.
8. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008;28:1584-95.
9. Gulati R, Jevremovic D, Peterson TE, et al. Autologous culture-modified mononuclear cells confer vascular protection after arterial injury. Circulation 2003;108:1520-6.
10. Hur J, Yoon CH, Kim HS, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004;24:288-93.
11. Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003;107:1164-9.
12. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000;105:71-7.
13. Zhang Y, Ingram DA, Murphy MP, et al. Release of proinflammatory mediators and expression of proinflammatory adhesion molecules by endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2009;296:1675-82.
14. Kawada H, Fujita J, Kinjo K, et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004;104:3581-7.
15. Simper D, Stalboerger PG, Panetta CJ, et al. Smooth muscle progenitor cells in human blood. Circulation 2002;106:1199-204.
16. Wang CH, Hsieh IC, Pang JH, et al. Factors associated with purity, biological function and activation potential of endothelial colony-forming cells. Am J Physiol Regul Integr Comp Physiol 2011;300:R586-94.
17. Liu P, Zhou B, Gu D, et al. Endothelial progenitor cell therapy in atherosclerosis: a double-edged sword? Ageing Res Rev 2009;8:83-93.
18. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999;5:434-8.
19. Halcox JP, Donald AE, Ellins E, et al. Endothelial function predicts progression of carotid intima-media thickness. Circulation 2009;119:1005-12.
20. Yeboah J, Crouse JR, Hsu FC, et al. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 2007;115:2390-7.
21. Tzoulaki I, Murray GD, Lee AJ, et al. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 2005;112:976-83.
22. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-6.
23. Dimmeler S, Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ Res 2008;102:1319-30.
24. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89:1-7.
25. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation 2003;108:2054-9.
26. Lin Y, Weisdorf DJ, Solovey A, et al. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000;105:71-7.
27. Assmus B, Honold J, Schächinger V, et al. Transcoronary transplantation of progenitor cells aftermyocardial infarction. N Engl J Med 2006;355:1222-32.
28. Kamihata H, Matsubara H, Nishiue T, et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001;104:1046-52.
29. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006;113:1287-94.
30. Schächinger V, Erbs S, Elsässer A, et al. REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210-21.
31. Hulthe J, Fagerberg B. Circulating oxidized LDL is associated with increased levels of cell-adhesion molecules in clinically healthy 58-year old men (AIR study). Med Sci Monit 2002;8:148-52.
32. Glowinska B, Urban M, Peczynska J, et al. Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes. Metabolism 2005;54:1020-6.
33. Kent JW Jr, Comuzzie AG, Mahaney MC, et al. Intercellular adhesion molecule-1 concentration is genetically correlated with insulin resistance, obesity, and HDL concentration in Mexican Americans. Diabetes 2004;53:2691-5.
34. Spigoni V, Picconi A, Cito M, et al. Pioglitazone improves in vitro viability and function of endothelial progenitor cells from individuals with impaired glucose tolerance. PLoS One 2012;7:e48283.
35. Fadini GP, Albiero M, Boscaro E, et al. Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells. Cell Biol Int 2010;34:709-15.
36. Huang CY, Lin FY, Shih CM, et a. Moderate to high concentrations of high-density lipoprotein from healthy subjects paradoxically impair human endothelial progenitor cells and related angiogenesis by activating Rho-associated kinase pathways. Arterioscler Thromb Vasc Biol 2012;32:2405-17.
37. Zhu J, Yang K, Jing Y, et al. The effects of low-dose nepsilon-(carboxymethyl)lysine (CML) and nepsilon-(carboxyethyl)lysine (CEL), two main glycation free adducts considered as potential uremic toxins, on endothelial progenitor cell function. Cardiovasc Diabetol 2012;11:90.
38. Cui X, Zhang X, Guan X, et al. Shear stress augments the endothelial cell differentiation marker expression in late EPCs by upregulating integrins. Biochem Biophys Res Commun 2012;425:419-25.
39. Masuda H, Kalka C, Takahashi T, et al. Estrogen-mediated endothelial progenitor cell biology and kinetics for physiological postnatal vasculogenesis. Circ Res 2007;101:598-606.
40. La Vignera S, Condorelli R, Vicari E, et al. Original immunophenotype of blood endothelial progenitor cells and microparticles in patients with isolated arterial erectile dysfunction and late onset hypogonadism: effects of androgen replacement therapy. Aging Male 2011;14:183-9.
41. Hermansen SE, Lund T, Kalstad T, et al. Adrenomedullin augments the angiogenic potential of late outgrowth endothelial progenitor cells. Am J Physiol Cell Physiol 2011;300:783-91.
42. Guven H, Shepherd RM, Bach RG, et al. The number of endothelial progenitor cell colonies in the blood is increased in patients with angiographically significant coronary artery disease. J Am Coll Cardiol 2006;48:1579-87.
43. Wang CH, Ciliberti N, Li SH, et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 2004;109:1392-400.
44. Wang CH, Hsieh IC, Chen SJ, et al. VE-cadherin(low)α-smooth muscle actin+ component of vascular progenitor cells correlates with the coronary artery Gensini score. Circ J 2012;76:477-84.
45. Wang CH, Hsieh IC, Cherng WJ, et al. Differentiation profile of peripheral blood-derived vascular progenitor cell predicts intimal hyperplasia after coronary stenting. Heart Vessels 2012;27:10-9.
46. Simper D, Mayr U, Urbich C, et al. Comparative proteomics profiling reveals role of smooth muscle progenitors in extracellular matrix production. Arterioscler Thromb Vasc Biol 2010;30:1325-32.
47. Zoll J, Fontaine V, Gourdy P, et al. Role of human smooth muscle cell progenitors in atherosclerotic plaque development and composition. Cardiovasc Res 2008;77:471-80.
48. van Oostrom O, Fledderus JO, de Kleijn D, et al. Smooth muscle progenitor cells: friend or foe in vascular disease? Curr Stem Cell Res Thera 2009;4:131-40.
49. Wong V, Stavar L, Szeto L, et al. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis 2006;184:348-55.
50. Hsu YH, Chen YC, Chen TH, et al. Far-infrared therapy induces the nuclear translocation of PLZF which inhibits VEGF-induced proliferation in human umbilical vein endothelial cells. PLoS One 2012;7:e30674.
51. Huang PH, Chen JW, Lin CP, et al. Far infra-red therapy promotes ischemia-induced angiogenesis in diabetic mice and restores high glucose-suppressed endothelial progenitor cell functions. Cardiovasc Diabetol 2012;11:99.
52. Huang PH, Lin CP, Wang CH, et al. Niacin improves ischemia-induced neovascularization in diabetic mice by enhancement of endothelial progenitor cell functions independent of changes in plasma lipids. Angiogenesis 2012;15:377-89.
53. Huang PH, Tsai HY, Wang CH, et al. Moderate intake of red wine improves ischemia-induced neovascularization in diabetic mice-roles of endothelial progenitor cells and nitric oxide. Atherosclerosis 2010;212:426-35.
54. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007;167:989-97.
55. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone-marrow cells: a pilot study and a randomized controlled trial. Lancet 2002;360:427-35.
56. Esato K, Hamano K, Li TS, et al. Neovascularization induced by autologous bone marrow cell implantation in peripheral arterial disease. Cell Transplant 2002;11:747-52.
57. Saigawa T, Kato K,Ozawa T, et al. Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells. Circ J 2004;68:1189-93.
58. Higashi Y, Kimura M, Hara K, et al. Autologous bone-marrow mononuclear cell implantation improves endothelium-dependent vasodilation in patients with limb ischemia. Circulation 2004;109:1215-8.
59. Miyamoto M, Yasutake M, Takano H, et al. Therapeutic angiogenesis by autologous bone marrow cell implantation for refractory chronic peripheral arterial disease using assessment of neovascularization by 99mTc-tetrofosmin (TF) perfusion scintigraphy. Cell Transplant 2004;13:429-37.
60. Hasebe H, Osada M, Kodama Y, et al. Therapeutic angiogenesis by autologous transplantation of bone-marrow cells in a patient with progressive limb ischemia due to arteriosclerosis obliterans: a case report. J Cardiol 2004; 3:179-83.
61. Nizankowski R, Petriczek T, Skotnicki A, Szczeklik A. The treatment of advanced chronic lower limb ischaemia with marrow stem cell autotransplantation. Kardiol Pol 2005;63:351-60.
62. Kajiguchi M, Kondo T, Izawa H, et al. Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J 2007;71:196-201.
63. Arai M, Misao Y, Nagai H, et al. Granulocyte colony-stimulating factor: a noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Circ J 2006;70:1093-8.
64. Matoba S, Tatsumi T, Murohara T, et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (TACT Trial) in patients with chronic limb ischemia. Am Heart J 2008;156:1010-8.
65. Tateno K, Minamino T, Toko H, et al. Critical roles of muscle-secreted angiogenic factors in therapeutic neovascularization. Circ Res 2006;98:1194-202.
66. Sugihara S, Yamamoto Y, Matsubara K, et al. Autoperipheral blood mononuclear cell transplantation improved giant ulcers due to chronic arteriosclerosis obliterans. Heart Vessels 2006;21:258-62.
67. Kawamura A, Horie T, Tsuda I, et al. Prevention of limb amputation in patients with limb ulcers by autologous peripheral blood mononuclear cell implantation. Ther Apher Dial 2005;9:59-63.
68. Kawamura A, Horie T, Tsuda I, et al. Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs 2006;9:226-33.
69. Hoshino J, Ubara Y, Hara S, et al. Quality of life improvement and long-term effects of peripheral blood mononuclear cell transplantation for severe arteriosclerosis obliterans in diabetic patients on dialysis. Circ J 2007;71:1193-8.
70. Huang PP, Yang XF, Li SZ, et al. Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost 2007;98:1335-42.
71. Horie T, Onodera R, Akamastu M, et al. Long-term clinical outcomes for patients with lower limb ischemia implanted with G-CSF-mobilized autologous peripheral blood mononuclear cells. Atherosclerosis 2010;208:461-6.
72. Inaba S, Egashira K, Komori K. Peripheral-blood or bone-marrow mononuclear cells for therapeutic angiogenesis? Lancet 2002;360:2083.
73. Kawamoto A, Katayama M, Handa N, et al. Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells 2009;27:2857-64.
74. Burt RK, Testori A, Oyama Y, et al. Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia. Bone Marrow Transplant 2010;45:111-6.
75. Sugiyama S, Kugiyama K, Nakamura S, et al. Characterization of smooth muscle-like cells in circulating human peripheral blood. Atherosclerosis 2006;187:351-62.
76. + cells and circulating cxcl12 correlate with the angiographically assessed severity of cardiac allograft vasculopathy. Euro Heart J 2011;32:476-84.
77. Metharom P, Liu C, Wang S, et al. Myeloid lineage of high proliferative potential human smooth muscle outgrowth cells circulating in blood and vasculogenic smooth muscle-like cells in vivo. Atherosclerosis 2008;198:29-38.
78. Wang CH, Lee YS, Lin SJ, et al. Surface markers of heterogeneous peripheral blood-derived smooth muscle progenitor cells. Arterioscler Thromb Vasc Biol 2012;32:1875-83.
79. Yoshioka S, Fujiwara H, Yamada S, et al. Membrane-bound carboxypeptidase-m is expressed on human ovarian follicles and corpora lutea of menstrual cycle and early pregnancy. Mole Hu Repro 1998;4:709-17.
80. Kuwasako K, Cao YN, Nagoshi Y, et al. Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins. Mole Pharma 2004;5:207-13.
81. Chiche J, Brahimi-Horn MC, Pouyssegur J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cellu Mol Med 2010;14:771-94.
82. Berthelemy N, Kerdjoudj H, Schaaf P, et al. O2 level controls hematopoietic circulating progenitor cells differentiation into endothelial or smooth muscle cells. PloS One 2009;4:e5514.
83. Oksala N, Levula M, Pelto-HuikkoM, et al. Carbonic anhydrases ii and xii are up-regulated in osteoclast-like cells in advanced human atherosclerotic plaques-tampere vascular study. Ann Med 2010;42:360-70.
84. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, et al. Ldl receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 2008;88:887-918.
85. Schulz S, Birkenmeier G, Schagdarsurengin U, et al. Role of ldl receptor-related protein (lrp) in coronary atherosclerosis. Int J Cardio 2003;92:137-44.
86. Lillis AP, Mikhailenko I, Strickland DK. Beyond endocytosis: Lrp function in cell migration, proliferation and vascular permeability. J Thromb Haemost 2005;3:1884-93.